Quadra Logic Technologies Inc. deal

QLTIF and CIBA Vision Ophthalmics will jointly develop on a worldwide basis QLTIF's Photodynamic Therapy as a treatment for eye disease. The first project will focus on age-related macular degeneration (AMD).

CIBA Vision will fund 60 percent of the development costs, with the Vancouver company responsible for the balance. The companies will share equally the profits from product sales, after deducting marketing and manufacturing costs and third-party royalties. ...